Compare Abbott Laboratories (ABT) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Thomson Reuters Corp — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Thomson Reuters Corp trades at $89 (market cap $39.64B). The key difference: Abbott Laboratories is far larger — about 4.2× Thomson Reuters Corp's market cap, and Thomson Reuters Corp pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| ABT | TRI | |
|---|---|---|
Market Cap | $166.94B | $39.64B |
Sector | Health | Industrials |
52-Week High | $136.62 | $214.21 |
52-Week Low | $82.57 | $76.55 |
Enterprise Value | $193.69B | $41.59B |
Dividend Yield | 2.63% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Thomson Reuters (TRI) trades at $90.76, up 1.74% with bullish technical indicators and strong analyst support. The company reported Q1 2026 EPS of $1.23, beating estimates, while revenue reached $7.48B in 2025. Recent corporate actions include a special dividend and reverse stock split. Technical analysis shows resistance near $92 with RSI indicating potential overbought conditions.
Outlook remains positive with a consensus price target of $129.96, though risks include AI implementation challenges and competitive pressures. Revenue growth is steady, but net income margin compression from 39.66% in 2023 to 20.09% in 2025 warrants monitoring. Institutional sentiment is bullish with 51.85% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
